Lab Med Online.  2020 Apr;10(2):95-108. 10.3343/lmo.2020.10.2.95.

Recommendations for Liquid Chromatography-Mass Spectrometry in the Clinical Laboratory: Part II. Method Validation

• Moon SY
• Choi HJ
• Kim S
• Lee K
• Lee SG
• Song SH
• Lee SY
• Park HD
• Clinical Mass Spectrometry Research Committee of theKorean Society of Clinical Chemistry

• KMID: 2512239
• DOI: http://doi.org/10.3343/lmo.2020.10.2.95

Abstract

The demand for obtaining test results using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate diagnosis in the field of laboratory medicine is expected to increase, but it is still not easy to introduce diagnostic methods using LC-MS/MS into clinical laboratories for many reasons. There are many different methods used to evaluate the performance of LC-MS/MS in clinical laboratories, which have not been standardized to date. Thus, various data have been analyzed and described based on the type of validation method used and the criteria needed to introduce a new test using LC-MS/MS in a clinical laboratory. Relevant data from home and abroad were reviewed to include the minimum number of validation items required and methods of implementation. In general, the items required for a full validation of the quantitative test and various guidelines were used to summarize the following validation items: accuracy, precision, calibration, specificity, ion suppression or improvement, limit of detection, limit of quantification, stability, reference interval, carryover, and dilution integrity. Among these, the first five items mentioned beforehand are essential parameters for LC-MS/MS validation and are presented in numerous guidelines. The other parameters are required for further verification depending on the characteristics of the analysis and the analytes. This recommendation is intended to outline and present the validation methods that should be carried out when introducing new tests in clinical laboratories using LC-MS/MS with reference to the existing guidelines and literature containing expert opinions.

Keyword

Liquid chromatography-tandem mass spectrometry; Recommendation; Validation; Clinical laboratories

Reference

1. U.S. Department of Health and Human Services Food and Drug Ad-ministrations. Bioanalytical method validation; Guidance for industry. Center for Drug Evaluation and Research, Food and Drug Administrations;Silver Spring, MD: May 2001.

2. European Medicines Agency, Guideline on bioanalytical method vali-dation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**. https://www. ema.europa.eu/en/documents/scientific-guideline/guideline-bioana-lytical-method-validation_en.pdf. Updated on Jun 2015.

3. Clinical and Laboratory Standards Institute. 2007; Mass spectrometry in the clinical laboratory: General principles and guidance; Approved Guideline. CLSI guideline C50-A. Clinical and Laboratory Stan-dards Institute;Wayne, PA:

4. Clinical and Laboratory Standards Institute. 2014; Liquid chromatography-mass spectrometry methods; Approved Guideline. CLSI guideline C62-A. Clinical and Laboratory Stan-dards Institute;Wayne, PA:

5. International Conference on Harmonisation, Validation of analytical procedures : text and methodology. ICH Guideline Q2(R1). http://www.gmp-compliance.org/guidemgr/files/Q2(R1).PDF. Updated on Nov 2005.

6. Thompson M, Ellison SLR, Wood R. 2002; Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC technical report). Pure Appl Chem. 74:835–55. DOI: 10.1351/pac200274050835.

7. Scientific Working Group for Forensic Toxicology. 2013; Scientific working group for forensic toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol . 37:452–74. DOI: 10.1093/jat/bkt054. PMID: 23934984.

8. Ministry of Food and Drug Safety. Bioanalytical method validation manual. http://www.korea.kr/common/download.do?tblKey=EDN&fileId=199088. Updated on Jun 2010.

9. Laboratory Medicine Foundation. 2019. Clinical laboratory accreditation checklist for clinical chemistry. Laboratory Medicine Foundation;Seoul:

10. Grant RP, Rappold BA. Rifai N, editor. Development and validation of small molecule analytes by liquid chromatography-tandem mass spectrometry. Tietz textbook of clinical chemistry and molecular diagnostics. 6th ed. Elsevier;St. Louis, MO: p. 326e1–e63.

11. Clinical and Laboratory Standards Institute. 2003; Evaluation of the linearity of quantitative measurement procedures: A statistical approach; Ap-proved Gguideline. CLSI document EP6-A. Clinical and Laboratory Standards Institute;Wayne, PA:

12. Clinical and Laboratory Standards Institute. 2005; Interference testing in clin-ical chemistry; Approved guideline-Second edition. CLSI document EP7-A2. Clinical and Laboratory Standards Institute;Wayne, PA:

13. Matuszewski BK, Constanzer ML, Chavez-Eng CM. 2003; Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC−MS/MS. Anal Chem . 75:3019–30. DOI: 10.1021/ac020361s. PMID: 12964746.

14. Clinical and Laboratory Standards Institute. 2012; Evaluation of detection ca-pability for clinical laboratory measurement procedures; Approved guideline-Second edition. CLSI guideline EP17-A2. Clinical and Laboratory Standards Institute;Wayne, PA:

15. Clinical and Laboratory Standards Institute. 2010; Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline-Third edition. CLSI guideline C28-A3. Clinical and Laboratory Standards Institute;Wayne, PA:

16. Haeckel R. 1988; Recommendations for definition and determination of carry-over effects. J Automat Chem. 10:181–3. DOI: 10.1155/S1463924688000380. PMID: 18925212. PMCID: PMC2547758.

17. Clinical and Laboratory Standards Institute. 2014; Preliminary evaluation of quantitative clinical laboratory measurement procedures; Approved guideline-Third edition. CLSI guideline EP10-A3-AMD. Clinical and Laboratory Standards Institute;Wayne, PA: